BioSpace News Archive

Deals

Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”).

March 3, 2022
·
11 min read
Recursion Provides Updated Guidance on Clinical Trial Starts

Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts.

March 3, 2022
·
4 min read
Pharm Country

Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.

March 3, 2022
·
1 min read
Business

Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

Genocea Biosciences, Inc. will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T.

March 3, 2022
·
2 min read
Pharm Country

VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

VYNE Therapeutics Inc. today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022.

March 3, 2022
·
1 min read
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.

March 3, 2022
·
4 min read
Pharm Country

TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLLFDA sets updated PDUFA goal date of June 25, 2022

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date to June 25, 2022 for the Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for ublituximab.

March 3, 2022
·
15 min read
Pharm Country

Insmed To Present at the Cowen 42nd Annual Health Care Conference

Insmed Incorporated today announced that management will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10 a.m. ET.

March 3, 2022
·
1 min read
FDA

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

I-Mab today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for TJ-CD4B, a novel Claudin 18.2 x 4-1BB.

March 3, 2022
·
6 min read
Pharm Country

ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance

ArrePath, announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).

March 3, 2022
·
8 min read